Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Income from Continuing Operations: 2020-2024

Historic Income from Continuing Operations for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Dec 2024 value amounting to -$115.6 million.

  • Tarsus Pharmaceuticals' Income from Continuing Operations rose 46.00% to -$12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.0 million, marking a year-over-year increase of 38.99%. This contributed to the annual value of -$115.6 million for FY2024, which is 14.97% up from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Income from Continuing Operations of -$115.6 million as of FY2024, which was up 14.97% from -$135.9 million recorded in FY2023.
  • Tarsus Pharmaceuticals' Income from Continuing Operations' 5-year high stood at -$13.8 million during FY2021, with a 5-year trough of -$135.9 million in FY2023.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$115.6 million (2024), whereas its average is -$104.5 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first skyrocketed by 48.43% in 2021, then slumped by 349.06% in 2022.
  • Over the past 5 years, Tarsus Pharmaceuticals' Income from Continuing Operations (Yearly) stood at -$26.8 million in 2020, then spiked by 48.43% to -$13.8 million in 2021, then plummeted by 349.06% to -$62.1 million in 2022, then slumped by 118.86% to -$135.9 million in 2023, then rose by 14.97% to -$115.6 million in 2024.